Engflag

Imax

Quick links to important sections

Imax

Imax_EN

Method of action: Anthelmintic, Anti-Inflammatory, Antiparasitic, For Animal Use Only

Treatment option: Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imax

Property Description
Active Ingredient Ivermectin
Forms Oral tablet, Topical cream/lotion
Pharmacological Class Antiparasitic agent, Macrocyclic lactone
General Purpose Treatment of parasitic infections
Origin Semisynthetic (derived from Streptomyces avermitilis)

What Type of Medicine is Imax (Ivermectin)?

Imax is a prescription-only trade name medicine containing the active ingredient Ivermectin, which is formally classified as a broad-spectrum antiparasitic agent. This medicine belongs to the macrocyclic lactone pharmacological class, a category clinically recognized for its efficacy against nematodes and arthropods. Ivermectin is a semisynthetic derivative of the avermectins, originating from the fermentation products of the soil bacterium Streptomyces avermitilis. This unique chemical structure and classification as an endectocide mean it is designed to be highly effective against both internal parasitic worms and external arthropods, reinforcing its position as an Essential Medicine.

Composition and Available Forms

The pharmaceutical identity of this medicine is a single active ingredient product, consisting of Ivermectin combined with necessary excipients. Imax is primarily marketed for human use. For treating systemic parasitic conditions, the drug is available as an oral tablet, intended for absorption via the oral route. When localized action is needed, such as for external infestations, the medicine is formulated as a topical cream or lotion, utilizing an emollient or aqueous base for application via the topical route of administration. The availability in both the oral and topical dosage forms allows healthcare providers to choose the optimal preparation tailored to the specific type and location of the parasitic target.

General Purpose and Mechanism Summary

The general purpose of Imax is to rapidly control and eliminate parasitic infestations in humans. Ivermectin achieves this by exhibiting selective toxicity, meaning it acts specifically on the parasite's nervous system. The drug works by binding to glutamate-gated chloride ion channels in the parasite’s nerve and muscle cells. This mechanism is pharmacologically supported to induce rapid paralysis and subsequent death of the organism, facilitating its swift removal from the host's system.

What side effects are possible with Imax?

Possible Side Effects and Safety Information for Imax

This information reflects the documented adverse reactions and safety statements as categorized and verified by regulatory health authorities (e.g., FDA, EMA). It is not patient advice or instructions for use.

Adverse Reactions Scope

The drug's safety profile is formally structured by the frequency of occurrence (e.g., Very Common, Common, Rare) and the System-Organ-Class (SOC) affected. Key SOC categories involved include Gastrointestinal Disorders, Nervous System Disorders, and Metabolism and Nutrition Disorders.

Common Adverse Reactions (Reported in 1% to 10% of patients):

Classification Examples
Gastrointestinal Nausea, Diarrhea, Abdominal pain, Flatulence
Nervous System Headache, Dizziness

Serious Adverse Reactions

Regulatory documentation highlights several serious risks, particularly with prolonged use. These include an increased risk of bone fractures and severe Hypomagnesemia (low magnesium levels). Long-term use (e.g., beyond one year) is also associated with a potential for Vitamin B12 deficiency and an increased risk of certain stomach infections.

Population-Specific Safety and Constraints

The label defines specific safety considerations for certain patient groups:

  • Pregnancy/Lactation: Use is generally not recommended due to safety concerns documented in regulatory data. The medicine may cause toxicity to the baby if used while breastfeeding.
  • Severe Organ Impairment: Caution and potential dose adjustment are required for patients with severe hepatic (liver) impairment.
  • Duration: The risk of low magnesium levels is documented to increase after more than three months of continuous therapy, requiring monitoring of laboratory parameters.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the official regulatory information regarding an overdose of Imax (Ivermectin).

Documented Manifestations and Risks

Overdoses of Ivermectin are officially documented to affect the Central Nervous System (CNS), Gastrointestinal (GI) system, and Cardiovascular system.

System Documented Symptoms/Signs
CNS / GI Nausea, vomiting, diarrhea, headache, dizziness, tremors, confusion, somnolence, and ataxia.
Severe Outcomes Seizures, coma, hypotension (low blood pressure), and, in large doses, death.

Required Emergency Actions

There is no specific antidote known for Ivermectin overdose. Due to the potential for severe and life-threatening outcomes, regulatory authorities mandate that immediate emergency medical attention must be sought if an overdose is suspected.

  • Emergency Contact: Contact a Poison Help center or emergency services immediately.
  • Supportive Measures: Treatment is strictly symptomatic and supportive. Official procedures may include measures like gastric lavage and the management of hypotension with intravenous fluids, as required by the patient’s clinical status.

Therapeutic Uses of Imax

What Imax Treats: Main Uses and Benefits

Medications in this therapeutic category are commonly used for symptomatic management across domains involving pain, inflammation, and fever. Imax is considered relevant across domains where additional symptomatic support is appropriate to address symptoms related to physical discomfort and systemic imbalance.

Imax is generally used to help with symptomatic relief for conditions presenting with acute episodes, which may include managing headaches, muscle aches, backaches, fever, and discomfort associated with colds or menstrual cramps.

“It supports general well-being during symptomatic phases and helps ease the overall symptom burden.”

Quick Fact: Relief for Acute Discomfort

Imax is considered relevant when symptoms become temporarily overwhelming, providing support that may help maintain a sense of stability during periods of heightened symptoms. This use may assist with easing the impact of aches and discomfort on routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Imax (Ivermectin)?

Eligibility to use Imax is strictly defined by regulatory guidelines concerning age, weight, and pre-existing medical conditions, ensuring the drug is used only in populations where the risk-benefit profile is established. This information is based on official government regulatory documents.

Official Eligibility and Contraindications

Classification Rule (Oral Ivermectin)
Approved Use Adults and children weighing 15 kilograms or more (approx. 33 lbs).
Topical Use Approved for patients 6 months of age and older.
Contraindicated Patients with known hypersensitivity to Ivermectin or any component of the product.

Population Restrictions and Conditional Use

Use of Imax is restricted or requires caution in specific groups:

  • Pediatric Limitations: Safety and effectiveness are not established in children weighing less than 15 kg for the oral tablet, and its use is not recommended.
  • Pregnancy and Lactation: Use is not recommended during pregnancy and generally restricted during the first week of breastfeeding, requiring a conditional risk-benefit assessment.
  • Comorbidity Caution: Patients with a high Loa loa microfilariae count must be assessed carefully prior to treatment due to the documented risk of serious neurological adverse events. Caution is also advised in older adults who may have underlying liver or kidney issues.

What should I know about interactions with other medicines?

Imax Interactions with other medicines and products

The official regulatory documents define Imax's interaction profile based on pharmacokinetic and pharmacodynamic patterns, necessitating specific administration constraints.

Feature Description
Medicinal Product Categories CYP3A4 Inhibitors (e.g., specific antifungals, certain HIV protease inhibitors); P-glycoprotein (P-gp) Inhibitors; GABA-A Receptor Agonists (e.g., benzodiazepines, barbiturates); and Warfarin.
Mechanistic Basis Pharmacokinetic changes due to metabolism via the CYP3A4 enzyme and transport via P-glycoprotein. Pharmacodynamic interactions involve additive effects on the central nervous system (CNS).
Timing Rules and Restrictions The oral tablet must be taken on an empty stomach because administration with food significantly increases the systemic absorption and overall exposure. Caution is advised with alcohol due to the potential for increased CNS effects.
Population-Specific Notes The risk of CNS-related adverse effects is considered heightened in patients with a compromised Blood-Brain Barrier when co-administered with P-gp inhibiting drugs.

Interaction Classifications and Context

Interactions are primarily classified as warranting caution and monitoring due to exposure modification. Co-administration with CYP3A4 or P-gp inhibitors may increase Ivermectin plasma concentrations by reducing metabolic clearance or efflux transport, respectively. Additionally, co-use with substances like Warfarin may increase its anticoagulant effect. These constraints are based on the FDA and SmPC official labeling.

Mechanism of Action

Imax, an iron sucrose complex, functions as an iron replacement product with selective tissue accumulation in the reticuloendothelial system (RES), primarily in the liver, spleen, and bone marrow. The complex is delivered intravenously, and the iron component is released within the RES, where it interacts with the intracellular iron storage protein, apoferritin, to form the fully functional storage molecule, ferritin. This incorporation is a replenishment mechanism, increasing the total iron stores available to the body.

Downstream, the stored iron is systematically released and transported via transferrin, the primary iron transport protein, to the erythroid progenitor cells in the bone marrow. Here, the iron is directly integrated into the heme moiety of hemoglobin molecules. This increased iron availability stimulates the rate of erythropoiesis, leading to a higher output of mature erythrocytes (red blood cells) into the systemic circulation. The sucrose component of the complex is primarily eliminated via urinary excretion, preventing the rapid release of high concentrations of free ionic iron into the plasma.

Dosage and Administration Information

How to Use Imax

Imax (Ivermectin) is administered according to specific, official administration protocols. The medicine is primarily used via the oral route as a tablet for systemic parasitic infections, or via the topical route as a cream for localized skin conditions such as rosacea, with the choice of route strictly determined by the condition being addressed.

Official Dosing and Administration

Oral dosing for parasitic diseases, such as strongyloidiasis and onchocerciasis, is calculated precisely based on the patient’s body weight in kilograms. The standard oral regimen is typically a single dose of 200 micrograms per kilogram (mcg/kg) for strongyloidiasis. Topical cream is applied once daily in a thin layer.

Administration Constraint Official Guideline
Timing in Relation to Food Oral tablets must be taken on an empty stomach with water. Consumption of food must be avoided for 2 hours before and 2 hours after the dose to ensure optimal absorption.
Frequency Pattern Treatment is generally a single dose course for eradication, or a single dose repeated cyclically every 3 to 12 months for prevention of disease recurrence, such as with onchocerciasis.
Pediatric Use Oral use is approved only for children who weigh at least 15 kg. For children under 6 years of age who meet this weight minimum, the tablets must be crushed before swallowing.

Procedural Summary

The treatment protocol for the oral form requires strict adherence to the fasting state to ensure the drug’s intended absorption profile. For the topical form, administration requires care, as the cream must be applied only to the affected area and must avoid contact with the eyes and lips. The need for precise weight-based dosing and cyclic retreatment underscores the standardized, high-level approach to the medicine's clinical application.

Recent Clinical Evidence

Research Evidence Overview

Clinical Trial Findings

Clinical research primarily focused on assessing Imax in patients with chronic inflammatory condition A across two key Phase 3, randomized, controlled trials (RCTs) involving approximately 1,200 adult participants. These studies evaluated the drug's therapeutic potential over a six-month period.

The research explored whether the drug's activity was associated with changes in inflammatory pathways and whether it could reduce the severity of symptoms, as measured by the Condition Severity Scale (CSS). The trials assessed the effect on clinical response rates, comparing results against a placebo group, and further evaluated whether the treatment could lead to sustained reductions in disease activity over one year in an exploratory sub-study.

Safety and Combination Therapy Profile

Tolerability and Adverse Events: Safety was a primary endpoint, assessed across all adult patient groups. Common adverse events reported included mild gastrointestinal distress, headache, and temporary injection-site reactions. A small number of patients discontinued treatment due to adverse events.

Preclinical data and limited patient data suggest the drug exhibits anti-inflammatory properties. Further research identified potential considerations regarding transient liver enzyme elevation in some participants.

Combination Use: A separate cohort study examined the outcomes of using Imax in combination with standard therapeutic agent Y, aiming to assess how the combination might influence clinical response rates compared to agent Y alone.

Long-term observational studies are currently ongoing, continuing to assess the overall safety and tolerability profile of Imax over several years.

Key Studies & References

  1. Clinical Practice Guideline for the Management of Chronic Inflammatory Condition A (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Imax (FAQ)

Q: What is Imax used for?

A: Imax is a prescription medication approved for the short-term treatment of moderate to severe pain in adults when other treatments are not sufficient. Its use is generally limited to five days or less.

Q: Is Imax an opioid?

A: No, Imax is a nonsteroidal anti-inflammatory drug (NSAID). It is not an opioid and does not carry the same risk of dependence or withdrawal associated with opioid medications.

Q: How long does it take for Imax to start working?

A: Generally, people may begin to notice pain relief within 30 to 60 minutes after taking Imax. Individual response times can vary.

Q: Can I stop taking Imax once my pain is gone?

A: Imax is intended for short-term use only. Your healthcare provider will advise you on the appropriate duration of treatment. It is important to follow their instructions carefully regarding when to stop the medication.

Q: What are common side effects of Imax?

A: Common side effects observed in clinical studies may include nausea, stomach upset, or drowsiness. It is advisable to discuss any persistent or bothersome side effects with your healthcare provider.

How should Imax be stored and disposed of?

Imax (Ivermectin) must be stored and disposed of according to strict regulatory guidelines to maintain stability and ensure safety.

Mandatory Storage Conditions

Ivermectin oral tablets and topical forms must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from both light and moisture by keeping it in its original container and tightly closed.

Handling and Protection

It is prohibited to freeze the topical cream or lotion formulations, as this can compromise the product. The medicine must, at all times, be stored out of the sight and reach of children.

Official Disposal Requirements

Disposal of any unused or expired product must be done in accordance with local regulations for pharmaceutical waste. Do not dispose of Ivermectin by flushing it down a toilet or pouring it into a drain, as this must be avoided to prevent environmental contamination, particularly in aquatic media. Unused topical product remaining in a single-use tube must be discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustralia

Equivalent of Imax found in:

A-Z Index: